Showing results (721-730 of 778) with videos related to

Sort By:
Pageof 78
American Journal of Nephrology|March 8, 2013
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)Dick de Zeeuw, Tadao Akizawa, Rajiv Agarwal, et al.
Annals of Internal Medicine|July 1, 2024
Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease : A Systematic Review and Retrospective Individual Participant-Level Meta-analysis of Clinical TrialsElaine Ku, Lesley A Inker, Hocine Tighiouart, et al.
The New England Journal of Medicine|July 16, 2011
MYO1E mutations and childhood familial focal segmental glomerulosclerosisCaterina Mele, Paraskevas Iatropoulos, Roberta Donadelli, et al.
American Heart Journal|May 3, 2005
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney diseaseT-Christian H Mix, Robert M Brenner, Mark E Cooper, et al.
Kidney International Reports|December 18, 2023
Efficacy and Safety of Iptacopan in Patients With C3 GlomerulopathyEdwin Wong, Carla Nester, Teresa Cavero, et al.
The New England Journal of Medicine|November 3, 2009
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney diseaseMarc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 23, 2018
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.
American Journal of Nephrology|November 21, 2022
Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor DanicopanSteven D Podos, Howard Trachtman, Gerald B Appel, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 1, 2021
Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challengesCarmine Zoccali, Alberto Ortiz, Inga Arune Blumbyte, et al.
Plos Medicine|January 14, 2021
Recognition and management of community-acquired acute kidney injury in low-resource settings in the ISN 0by25 trial: A multi-country feasibility studyEtienne Macedo, Ulla Hemmila, Sanjib Kumar Sharma, et al.
Pageof 78